Vector Inc.

6058.T
Advertising Agencies
2026/03/03 Updated
Market Cap: $417.0M (¥65.2B)
Stock Price: $8.89 (¥1,389)
Exchange Rate: 1 USD = ¥156.25

Announcement of Listing Approval for Consolidated Subsidiary (Vitabrid Japan Co., Ltd.)

Vector Inc.’s consolidated subsidiary Vitabrid Japan Co., Ltd. to newly list on the Tokyo Stock Exchange Growth Market on April 2, 2026. Public offering of 1,640,000 shares and a secondary offering of 246,000 shares via overallotment are planned.

Importance:
Page Updated: February 27, 2026
IR Disclosure Date: February 27, 2026

Key Figures

  • Number of shares in public offering: 1,640,000 shares
  • Number of overallotment shares: 246,000 shares (maximum)
  • Our shareholding ratio (post-listing): 66.5% (assuming no exercise of overallotment)

AI要約

About Vitabrid Japan's Listing

Vitabrid Japan Co., Ltd., a consolidated subsidiary of Vector Inc., has been approved for a new listing on the Tokyo Stock Exchange Growth Market. Established in 2014, the company is a D2C production company that offers wellness care products such as supplements and has a strong presence in the domestic D2C sector. The listing aims to enhance brand recognition and credibility, secure talented personnel, and strengthen business operations under an independent management structure.

Overview of Share Offering and Future Outlook

Alongside Vitabrid Japan’s listing, a public offering of 1,640,000 shares and a secondary offering of up to 246,000 shares via overallotment are planned. Consequently, Vector Inc.’s shareholding ratio will decrease from 95.4% to 66.5% (potentially down to 63.6%). However, it will continue to maintain its capital relationship as a consolidated subsidiary and promote group-wide growth. There will be no impact on consolidated financial results for the current fiscal year due to the listing; however, the company aims to enhance group corporate value in the medium to long term.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.